Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.
Lancet Diabetes EndocrinolJul 6, 2026 (epub)
Jing Luo, Sylvia Kehlenbrink, Chung-Chou H Chang et al.
✦ AI-curated · Sources linked
In 30 seconds
The HumAn-1 trial was a multicentre, open-label, randomised controlled trial assessing insulin glargine versus human isophane insulin in children and young adults with type 1 diabetes in low-resource settings. Among 400 participants, there was no significant difference in time in very low range (3.6% vs 3.4%) or time in target range (40.5% vs 38.1%) at 6 months, with p-values of 0.63 and 0.71, respectively.
Key findings
- Mean time in very low range was 3.6% for glargine and 3.4% for usual care, p=0.63.
- Mean time in target range was 40.5% for glargine and 38.1% for usual care, p=0.71.
- Serious adverse events occurred in 3% of the glargine group and 6% of the usual care group.
Why it matters
This study highlights the need for effective insulin management strategies in low-resource settings, as insulin glargine did not demonstrate significant benefits over traditional human insulins in this population.